BNGO: Bionano Price to Sales
Bionano Genomics, Inc. (BNGO) has achieved a breakthrough in the diagnosis of rare pathologies by creating an optical DNA structure mapping system. The current P/S multiple reflects market expectations, with the 0.40 mark indicating the asset's current valuation. Business stability is supported by a neutral geopolitical status and equipment procurement via long-term grants, which mitigates the impact of macroeconomic shocks.
Analytical breakdowns for Bionano (BNGO)
- market value and analyst target forecast:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Bionano Genomics, Inc.|BNGO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Bionano Genomics|BNGO - Company Aggregate Debts|Debt to Book Value Bionano Genomics|BNGO - Company Long-Term Debt|Short-Term Debt Volume Bionano Genomics|Intermediate Coverage Ratio bionanogenomics.com
- net income and valuation multiples indicators:
BNGO - Net Profit|Company Profit Forecast Bionano Genomics, Inc.|BNGO - Price to Earnings Ratio|Price to Future Earnings Ratio Bionano Genomics|BNGO - PEG Multiple|Enterprise Value to EBITDA Ratio Bionano Genomics, Inc.|BNGO - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Bionano Genomics|BNGO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months bionanogenomics.com|BNGO - Earnings per share growth in current year|Projected earnings per share growth rate for next year Bionano Genomics, Inc.
- total revenue and sales volume data:
General company analysis:BNGO (Bionano Genomics, Inc.)
The P/S ratio determines the market value of a business relative to its annual revenue, allowing for an assessment of an asset's overvaluation in the absence of net profit. By analyzing the P/S chart, an investor compares market expectations with the monetization rates of innovations from the elite geneticists at Bionano Genomics, Inc. (BNGO), whose developments in genome mapping create the fundamental basis for future capitalization growth.
Competitors of Bionano Genomics, Inc.
TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|OCGN - P/S Multiple|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Design Therapeutics, Inc.|RCKT: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Revenue Ratio|SLN - Price-to-Revenue Ratio|Price-to-Revenue Multiple ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Market Cap to Revenue|Sangamo Therapeutics Inc. (SGMO) - P/S Multiple|Price-to-Revenue Ratio Nautilus Bio|Price to Sales Metagenomi Therapeutics MGX|Price-to-Revenue Ratio Precision BioSciences (DTIL)|GBIO - Price to Sales|P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Market Cap to Revenue|IMNN - Price-to-Revenue Ratio|Price to Sales Phio Pharmaceuticals Corp|MBIO: P/S Multiple|TransCode (RNAZ) - P/S Multiple|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio
